Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers - PubMed (original) (raw)
. 2009 Jul 15;125(2):353-5.
doi: 10.1002/ijc.24379.
Affiliations
- PMID: 19378339
- DOI: 10.1002/ijc.24379
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Mi Ran Kang et al. Int J Cancer. 2009.
Abstract
Missense somatic mutations in IDH1 gene affecting codon 132 have recently been reported in glioblastoma multiforme (GBM) and other gliomas. The recurrent nature of the IDH1 mutations in the same amino acid strongly suggests that the mutations may play important roles in the pathogenesis of glial tumors. The aim of this study was to see whether the IDH1 codon 132 mutations occur in other human cancers besides glial tumors. We also attempted to confirm the occurrence of the IDH1 mutations in GBM of Korean patients. We have analyzed 1,186 cancer tissues from various origins, including carcinomas from breast, colon, lung, stomach, esophagus, liver, prostate, urinary bladder, ovary, uterine cervix, skin and kidney, and malignant mesotheliomas, primary GBM, malignant meningiomas, multiple myelomas and acute leukemias by single-strand conformation polymorphism analysis. We found four IDH1 codon 132 mutations in the GBM (4/25; 16.0%), two in the prostate carcinomas (2/75; 2.7%) and one in the B-acute lymphoblastic leukemias (B-ALL) (1/60; 1.7%), but none in other cancers. The IDH1 mutations consisted of five p.R132H and two p.R132C mutations. The data indicate that IDH1 codon 132 mutations occur not only in GBM, but also in prostate cancers and B-ALL. This study suggests that despite the infrequent incidence of the IDH1 mutations in prostate cancers and B-ALL, mutated IDH1 could be therapeutically targeted in these cancers and in glial tumors with the IDH1 mutations.
Copyright 2009 UICC.
Similar articles
- IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A. Bleeker FE, et al. Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937. Hum Mutat. 2009. PMID: 19117336 - Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Balss J, et al. Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5. Acta Neuropathol. 2008. PMID: 18985363 - Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW, Boisselier B, Rossetto M, Marie Y, Idbaih A, Mokhtari K, Gousias K, Hoang-Xuan K, Delattre JY, Simon M, Labussière M, Sanson M. Wang XW, et al. Cancer. 2013 Feb 15;119(4):806-13. doi: 10.1002/cncr.27798. Epub 2012 Nov 26. Cancer. 2013. PMID: 23184331 - IDH mutations in glioma and acute myeloid leukemia.
Dang L, Jin S, Su SM. Dang L, et al. Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Trends Mol Med. 2010. PMID: 20692206 Review. - The Importance of Mutational Drivers in GBM.
Kalkan R. Kalkan R. Crit Rev Eukaryot Gene Expr. 2016;26(1):19-26. doi: 10.1615/CritRevEukaryotGeneExpr.v26.i1.30. Crit Rev Eukaryot Gene Expr. 2016. PMID: 27278882 Review.
Cited by
- Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.
Carosi F, Broseghini E, Fabbri L, Corradi G, Gili R, Forte V, Roncarati R, Filippini DM, Ferracin M. Carosi F, et al. Cancers (Basel). 2024 Aug 2;16(15):2752. doi: 10.3390/cancers16152752. Cancers (Basel). 2024. PMID: 39123479 Free PMC article. Review. - Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.
Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz RM, Velasco G, Gonzalez-Menendez P, Dando I. Ambrosini G, et al. Cell Commun Signal. 2024 Jan 12;22(1):36. doi: 10.1186/s12964-023-01462-0. Cell Commun Signal. 2024. PMID: 38216942 Free PMC article. Review. - Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli G, Sbaraglia M, Angelini A, Bellan E, Pala E, Belluzzi E, Pozzuoli A, Borga C, Dei Tos AP, Ruggieri P. Trovarelli G, et al. Clin Orthop Relat Res. 2024 Jan 3;482(6):947-56. doi: 10.1097/CORR.0000000000002960. Online ahead of print. Clin Orthop Relat Res. 2024. PMID: 38170705 - Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.
Nahar Metu CL, Sutihar SK, Sohel M, Zohora F, Hasan A, Miah MT, Rani Kar T, Hossain MA, Rahman MH. Nahar Metu CL, et al. Cancer Rep (Hoboken). 2023 Oct;6(10):e1889. doi: 10.1002/cnr2.1889. Epub 2023 Sep 7. Cancer Rep (Hoboken). 2023. PMID: 37675821 Free PMC article. Review. - The Interplay between Dysregulated Metabolism and Epigenetics in Cancer.
Bassal MA. Bassal MA. Biomolecules. 2023 Jun 5;13(6):944. doi: 10.3390/biom13060944. Biomolecules. 2023. PMID: 37371524 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous